Generative AI is biology’s new playground. The technology powering popular chatbots can also dream up new, entirely novel versions of life’s most basic molecules, from DNA to proteins. Once the domain ...

A comprehensive bio-based design strategy defines the proposal. Buildings employ cross-laminated timber with timber-frame walls insulated using straw and wood fibre, while facades incorporate reused ...

Materials informatics sits at the intersection of experimental science, computation, and data analytics. The aim is simple: use data and models to make discovering, designing, and deploying new ...

Jeff Bezos has had quite a hectic week, having just concluded his third venture capital investment in a promising artificial intelligence startup. This time, the recipient of Bezos’s largesse is a ...

OpenAI is partnering with Hon Hai Precision Industry Co. to design and manufacture hardware for data centers, the latest move by the ChatGPT-maker to meet its surging need for infrastructure to ...

IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced ...

A new 12-kW reference design for high-performance power-supply units (PSUs) from Infineon Technologies is specifically designed for AI data centers and server applications. The reference design uses a ...

Design for manufacturing (DfM) is evolving from traditional engineering practices into a data-intensive discipline that requires real-time integration of manufacturing capabilities, supplier ...

In Atlanta, Microsoft has flipped the switch on a new class of datacenter – one that doesn’t stand alone but joins a dedicated network of sites functioning as an AI superfactory to accelerate AI ...

Behind layers of plaster, paint, and finishes lies an intricate network of pipes, electrical conduits, beams, and other structural elements that make a building function and stand, yet remain ...

Shares of Cogent Biosciences (COGT) climbed ~120% in the premarket on Monday after the company disclosed encouraging late-stage trial data for its lead asset, bezuclastinib, against a form of ...